MEI Pharma (MEIP) to Consider Strategic Alternatives
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Brookline Capital Markets Downgrades MEI Pharma (MEIP) to Hold
July 22, 2024 11:52 AM EDTBrookline Capital Markets analyst Leah Rush Cann downgraded MEI Pharma (NASDAQ: MEIP) from Buy to Hold.
The analyst comments "We cover MEI Pharma, a development-stage biotechnology company working in the PI3K pathway, CDK inhibition, epigenetics, and cancer metabolism, and... More



